Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide for skeletal muscle mitochondrial dysfunction in the elderly
NCT02245620Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Jan 2015
- Primary completion
- Jul 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mitochondrial myopathies (MM) comparing Elamipretide with Placebo (2 arms). Primary endpoint: Change From Baseline in ATPmax (Maximal ATP Synthetic Rate) at Day 7. Started Jan 2015; status: completed.
02
Drugs
elamipretide
03
Conditions
Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on NCT02245620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245620.